Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Celltrion
Biotech
Celltrion pens $744M pact for 2 preclinical autoimmune drugs
Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical assets from U.S. biotech Kaigene.
James Waldron
Nov 4, 2025 6:15am
Celltrion tacks on a 3rd Class I recall for rapid COVID tests
Apr 29, 2022 11:52am
Celltrion hit with 2nd Class I recall in a month for COVID tests
Mar 24, 2022 10:47am
FDA condemns another round of unauthorized COVID tests
Mar 2, 2022 10:50am
Celltrion's COVID-19 antibody cuts hospitalizations, deaths
Jun 14, 2021 10:30am
Iksuda raises $47M to take antibody-drug conjugate into clinic
Jun 7, 2021 8:20am
